HC Wainwright Issues Pessimistic Forecast for Voyager Therapeutics (NASDAQ:VYGR) Stock Price

Voyager Therapeutics (NASDAQ:VYGR) had its price objective dropped by analysts at HC Wainwright from $30.00 to $25.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 491.72% from the company’s previous close.

A number of other brokerages also recently commented on VYGR. Weiss Ratings reissued a “sell (d)” rating on shares of Voyager Therapeutics in a research report on Wednesday, October 8th. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Voyager Therapeutics in a research note on Tuesday. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.12.

Voyager Therapeutics Price Performance

Shares of Voyager Therapeutics stock traded down $0.04 during trading on Wednesday, hitting $4.23. 164,834 shares of the company were exchanged, compared to its average volume of 571,643. The firm has a market capitalization of $234.36 million, a P/E ratio of -1.96 and a beta of 0.95. The firm’s fifty day moving average price is $4.54 and its 200 day moving average price is $3.72. Voyager Therapeutics has a 1-year low of $2.64 and a 1-year high of $7.44.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.06. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 46.59%. The business had revenue of $13.37 million for the quarter, compared to analyst estimates of $7.86 million. As a group, equities research analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, CFO Nathan D. Jorgensen sold 7,666 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $4.78, for a total value of $36,643.48. Following the transaction, the chief financial officer directly owned 123,834 shares of the company’s stock, valued at approximately $591,926.52. The trade was a 5.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of large investors have recently modified their holdings of the company. Armistice Capital LLC boosted its position in shares of Voyager Therapeutics by 0.7% during the 1st quarter. Armistice Capital LLC now owns 5,436,000 shares of the company’s stock valued at $18,374,000 after acquiring an additional 40,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Voyager Therapeutics by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company’s stock worth $15,178,000 after acquiring an additional 40,147 shares during the last quarter. Vestal Point Capital LP grew its position in Voyager Therapeutics by 1.6% in the first quarter. Vestal Point Capital LP now owns 1,249,418 shares of the company’s stock worth $4,223,000 after acquiring an additional 19,418 shares in the last quarter. Geode Capital Management LLC lifted its stake in Voyager Therapeutics by 1.1% during the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock worth $3,474,000 after purchasing an additional 11,929 shares during the last quarter. Finally, Erste Asset Management GmbH increased its position in shares of Voyager Therapeutics by 5.5% during the 1st quarter. Erste Asset Management GmbH now owns 1,116,793 shares of the company’s stock valued at $3,826,000 after purchasing an additional 58,415 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.